Effects and safety of rituximab in systemic sclerosis: an analysis from the European Scleroderma Trial and Research (EUSTAR) groupSuzana Jordan, Thierry Zénone, Emmanuel Chatelus et al.|Annals of the Rheumatic Diseases|2014Cited by 432
Incidence and risk factors for gangrene in patients with systemic sclerosis from the EUSTAR cohortCarina Mihai, Dorota Krasowska, Oliver Distler et al.|Lara D. Veeken|2019Cited by 29
Deep hierarchical subtyping of multi-organ systemic sclerosis trajectories - a EUSTAR studyCécile Trottet, Claudia Ickinger, Manuel Schürch et al.|npj Digital Medicine|2025Cited by 5
Preventive effects of early immunosuppressive treatment on the development of interstitial lung disease in systemic sclerosisArthiha Velauthapillai, Lidia P Ananieva, Merle F. R. Bootsma et al.|Lara D. Veeken|2024Cited by 4
Does the Impact of <scp>COVID</scp>‐19 on Patients With Systemic Sclerosis Change Over Time?Elisabeth Deibel, Fabian A. Mendoza, Patrícia Carreira et al.|Arthritis Care & Research|2023Cited by 2